131466Formulation Feasibility: The Optimal Dosage Form For An Oral Domain AntibodyClosedFeasibility StudiesInnovate UKVHsquared Ltd is a venture funded , UK biotechnology company exploiting a novel oral antibody platform and low cost manufacturing process to bring ground breaking products to the market in infectious and auto-immune inflammatory diseases. This TSB grant application supports the formulation stage of development of a new modality for inflammatory bowel disease that can be taken orally. The formulation will allow our VHsquared stabilised domain antibodies to achieve maximum effect. Antibody therapies have revolutionised IBD treatment during the last decade but require injection, are expensive to manufacture, have safety considerations, and are subject to loss of response over time. VHsquared intends to harness the dramatic clinical impact of injectable antibody therapeutics and by developing an oral alternative with a superior profile, benefit both patients and healthcare providers.